Over 200 communicators.
Over 4,000,000 impressions.
Reach Over 250,000 Twitter accounts.
Hundreds of tweets.
1 Transparent Conversation
The Power of a Twitter Chat
Today Novo Nordisk published its 2013 Annual Report detailing the company's social, environmental and financial results for 2013.
Submitted by: Novo Nordisk
Posted: Feb 03, 2014 – 10:00 AM EST
NOVO ALLE, Denmark, Feb. 03 /CSRwire/ - Today Novo Nordisk published its 2013 Annual Report detailing the company’s social, environmental and financial results for 2013. The report highlights the company’s progression towards long-term targets during a year of challenges and setbacks. Novo Nordisk has taken an integrated approach to reporting since 2004, accounting for social, environmental and financial performance.
“Integrated reporting reflects our approach to doing business in a way that seeks to be both profitable and responsible. It shows how Novo Nordisk activates its resources to benefit patients and communities, while seeking to minimise our environmental impacts," says Lise Kingo, executive vice president, corporate relations, Novo Nordisk.
In the 2013 report, Novo Nordisk looks at how external events and stakeholder expectations are shaping the pharmaceutical industry and the public health agenda. Articles in the report include the global rise in diabetes, public trust in the pharmaceutical industry and address the question of obesity as a disease.
Novo Nordisk’s 2013 social and environmental performance includes:
Download the report
Novo Nordisk’s Annual Report 2013 is available as a downloadable PDF.
Novo Nordisk values feedback and welcomes questions or comments about its reporting and performance at firstname.lastname@example.org.
In the absence of global standards for inclusive reporting, the report was prepared in respect of international standards for mandatory and voluntary reporting, including:
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
For more information, visit novonordisk.com/sustainability.
For more information, please contact:
For more from this organization:Novo Nordisk